• Sign In
  • Register
  • Glossary
  • Share/Bookmark
  • RSS

FDA Grants Orphan Drug Designation to rVIIa-FP

FDA Grants Orphan Drug Designation to rVIIa-FP

Novel Therapy in Development to Treat Hemophilia A and Hemophilia B Patients Who Have Inhibitors Learn More

Tell Us About You

If you regularly experience nosebleeds, how long do they last?





Bleeding Disorders

  • von Willebrand Disease
  • Hemophilia A
  • Hemophilia B
  • Rare Bleeding Disorders

Patients &
Caregivers

Read Pablo's Story

Pablo's Story

Entrepreneur with hemophilia B focuses on his goals. Read his story and others. Learn More

Learn More

Coagulation Factor
Committed to WFH

CSL Behring will donate FVIII concentrate to improve treatment in developing countries. Learn More

Patients and Caregivers

Discussion Guides

Choose and use a convenient Discussion Guide, to guide your conversation with doctors, teachers or employers. Learn More

Healthcare Professionals

rIX-FP Phase I Trial Results Presented during GTH

rIX-FP Phase I Trial Results Presented During GTH

Clinical safety and improved pharmacokinetics compared to current treatment options. Learn More

Site Initiated for Phase II/III rIX-FP Study

Site Initiated for Phase II/III
rIX-FP Study

Phase I trial showed “promising" half-life extension results. Learn More

Key Issues Dialogue - Albumin

Key Issues Dialogue:
Albumin in Clinical Fluid Management

Pros and cons of albumin in volume replacement. Learn More